#USA #Palo Alto #DELFI Diagnostics #Lung Cancer #FANSS Study

Preliminary Findings from the FANSS Study

In a groundbreaking announcement, DELFI Diagnostics, a leading innovator in blood-based cancer detection technology, has released preliminary data from the Female Asian Nonsmoker Screening Study (FANSS). This pivotal study was presented at the ESMO Asia 2025 conference held in Singapore, igniting discussions around lung cancer screening for women who have never smoked. The FANSS study is particularly significant as it shines a spotlight on a demographic often overlooked in traditional lung cancer screening guidelines.

Understanding the Study

The FANSS study is aimed at investigating the feasibility of early lung cancer detection in a unique patient population - Asian American women with no history of smoking. Lung cancer is an alarming health issue, particularly among individuals who have never smoked, but existing screening protocols rarely account for these patients. The study highlights the elevated risk faced by this group, although the exact causes remain unidentified.

Researchers enrolled 1,000 participants in the study, conducting baseline low-dose computed tomography (LDCT) scans alongside a new cfDNA fragmentomics blood test. Out of those screened, 13 women were diagnosed with invasive lung adenocarcinoma, marking a 1.3% detection rate. This figure is remarkably higher than what has traditionally been observed in heavy smokers within the framework of the National Lung Screening Trial.

Key Findings

Dr. Elaine Shum, an oncologist and the study’s leading investigator, expressed concern about the rising incidence of lung cancer among non-smokers. The results from the FANSS study indicate a crucial need for tailored screening methods. With nine out of the 13 detected cancers classified as Stage IA, the findings underline the potential of identifying lung cancer at a more manageable, early stage.

Amoolya Singh, the Chief Technology Officer for DELFI Diagnostics, emphasized the importance of integrating plasma biomarker analysis into screening programs. He stated, “These results demonstrate the feasibility of incorporating plasma biomarker analysis into screening studies for high-risk populations who currently lack formal guidelines.” The study's focus on women aged 40-74 with minimal or no smoking history is especially timely, given the unique health challenges these individuals face.

The Technology Behind the Test

DELFI Diagnostics has pioneered the development of blood test technologies that leverage the characteristics of cancer cells in the bloodstream. Their tests, particularly the FirstLook Lung test, utilizes cfDNA fragmentomics. This entails examining the patterns of fragmented DNA released by dying cancer cells into the bloodstream. By employing advanced machine-learning algorithms, DELFI’s platform enables the accurate detection of early-stage lung cancer, achieving a staggering negative predictive value of 99.8%.

The simplicity of this blood test means it can be easily integrated into routine medical checkups, positioning it as a viable alternative to standard imaging tests that may not be accessible to all individuals.

Future Implications

With the FANSS study's findings, there's an optimistic outlook for blood-based screening methods to broaden lung cancer detection capabilities among non-smoking populations. This research not only propels DELFI Diagnostics to the forefront of innovation in cancer detection but also highlights the urgent need for tailored health interventions for high-risk groups.

As ongoing follow-ups continue with additional participants, the findings from the FANSS study are anticipated to contribute to developing comprehensive screening guidelines that encompass these often-neglected demographics. The data from this study will undoubtedly inform future protocols and enhance our understanding of lung cancer risks among non-smokers.

In conclusion, as our knowledge of lung cancer expands, the developments in the FANSS study may pave the way for more accessible and effective screening processes, ultimately helping in mitigating lung cancer's impact on society.

Conclusion

The FANSS study not only marks a significant step forward in the quest for more inclusive and effective cancer detection methods but also highlights the pressing need for continued research and innovation in the domain of cancer screening. As DELFI Diagnostics and collaborating researchers work to refine and validate these findings, the medical community and patients alike await more comprehensive solutions for preventing and detecting lung cancer in populations that have historically been underserved.